Integrating pharmacogenetics and therapeutic drug monitoring: Optimal dosing of imatinib as a case-example

European Journal of Clinical Pharmacology

Volumn 66, Issue 4, 2010, Pages 369-374

  Li Wan Po, Alain ^a   Farndon, Peter ^a   Craddock, Charles ^b   Griffiths, Michael ^c  

^a BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Chronic myeloid leukaemia; Imatinib resistance; Personalized medicine; Therapeutic drug monitoring

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DASATINIB; IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1; NILOTINIB; RIFAMPICIN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG CLEARANCE; DRUG COMPETITION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLUID RETENTION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; OPTIMAL DRUG DOSE; PHARMACOGENETICS; PRIORITY JOURNAL; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; BLOOD; GENETICS; MUTATION; TREATMENT OUTCOME;

DRUG MONITORING; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PHARMACOGENETICS; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 77953952853     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0779-4     Document Type: Article

References (44)

1. Schwartz R (2002) A molecular star in the wars against cancer. N Engl J Med 347(7):462-463
2. Demetri GDvMM, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. A molecular star in the wars against cancer. N Engl J Med 347:472-480
3. Wardelmann E, Thomas N, Merkelbach-Bruse S, Pauls K, Speidel N, Buttner R et al (2005) Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 6(4):249-251
4. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S et al (2003) Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101(2):473-475
5. Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M et al (2009) Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 115(3):551-560 (Pubitemid 36077567)
6. Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N et al (2009) Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 113 (10):2154-2160
7. Thomas J, Wang L, Clark RE, Pirmohamed M (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104(12):3739-3745
8. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA et al (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109(8):3496-3499
9. Singh N, Kumar L, Meena R, Velpandian T (2009) Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur J Clin Pharmacol 65(6):545-549
10. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111 (8):4022-4028
11. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11):994-1004
12. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408-2417 (Pubitemid 36302244)
13. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408-2417 (Pubitemid 36302244)
14. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344(14):1052-1056 (Pubitemid 44903745)
15. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344(14):1052-1056
16. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346(9):645-652
17. Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S et al (2002) Imatinib mesylate for Philadelphia chromosomepositive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 8(7):2177-2187
18. Baccarani M, Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Abruzzese E et al (2009) Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphiapositive chronic myeloid leukemia: a European LeukemiaNet study. Blood 113(19):4497-4504
19. Science and Technology Committee (2009) Genomic medicine, vol 1. House of Lords, London
20. Mauro MJ (2009) Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Cancer Control 16(2):108-121
21. Pollack A (2009) As pills treat cancer, insurance lags behind. New York Times 2009, April 15th:A1
22. Steinbrook R (2008) Saying no isn't NICE-the travails of Britain's National Institute for Health and Clinical Excellence. N Engl J Med 359(19):1977-1981
23. Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K et al (2009) Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 15(14):4750-4758
24. Quintas-Cardama A, Kantarjian HM, Cortes JE (2009) Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 16(2):122-131
25. Volpe G, Panuzzo C, Ulisciani S, Cilloni D (2009) Imatinib resistance in CML. Cancer Lett 274(1):1-9
26. Garg RJ, Kantarjian H, O'Brien S, Quintas-Cardama A, Faderl S, Estrov Z et al (2009) The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 114(20):4361-4368
27. Quintas-Cardama A, Cortes J (2009) Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy? Curr Oncol Rep 11(5):337-345
28. Jabbour E, Cortes J, Kantarjian H (2009) Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol 4 (1):3-10
29. Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44(9):879-894
30. Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G et al (2006) Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 80(2):192-201
31. Li-Wan-Po A, Farndon P, Cooley C, Lithgow J (2010) When is a genetic test suitable for prime time? predicting the risk of prostate cancer as a case-example. Public Health Genomics 13:55-62. doi:10.1159/000218710
32. Li-Wan-Po A (2010) Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol. doi:10.1111/j.1365-2125.2009.03578.x
33. Meyer zu Schwabedissen HE, Kim RB (2009) Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms. Mol Pharm 6(6):1644-1661
34. Willson TM, Kliewer SA (2002) PXR, CAR and drug metabolism. Nat Rev Drug Discov 1(4):259-266
35. Burk O, Wojnowski L (2004) Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch Pharmacol 369(1):105-124
36. Takagi S, Nakajima M, Mohri T, Yokoi T (2008) Posttranscriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem 283(15):9674-9680
37. Mishra PJ, Merlino G (2009) MicroRNA reexpression as differentiation therapy in cancer. J Clin Invest 119(8):2119-2123
38. Benet LZ (2009) The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol Pharm 6(6):1631-1643
39. Gurney H, Wong M, Balleine RL, Rivory LP, McLachlan AJ, Hoskins JM et al (2007) Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther 82(1):33-40
40. Petain A, Kattygnarath D, Azard J, Chatelut E, Delbaldo C, Geoerger B et al (2008) Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res 14(21):7102-7109
41. Dressman MA, Malinowski R, McLean LA, Gathmann I, Capdeville R, Hensley M et al (2004) Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571). Clin Cancer Res 10(7):2265-2271
42. McLean LA, Gathmann I, Capdeville R, Polymeropoulos MH, Dressman M (2004) Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clin Cancer Res 10(1 Pt 1):155-165
43. Bolton AE, Peng B, Hubert M, Krebs-Brown A, Capdeville R, Keller U et al (2
44. O'Brien SG, Meinhardt P, Bond E, Beck J, Peng B, Dutreix C et al (2003) Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate (Pubitemid 38445683)